Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Dexmedetomidine is a relatively selective alpha2-adrenoreceptor agonist with sedative pharmacologic properties.”
“Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: rapid distribution phase with a distribution half-life (t½) of about six minutes; terminal elimination half-life (t½) of approximately two hours; steady-state volume of distribution (Vss) of approximately 118 litres.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro studies indicate that clinically relevant cytochrome P450 mediated drug interactions are unlikely. Dexmedetomidine has shown strongest properties for inhibition of CYP2D6, CYP3A4 and CYP2B6.”